BIVI (BioVie) Wutah bathi EPS kuartalan

BioVie Inc. (BIVI) maintains a high scientific standing in the therapy of neurodegeneration and liver pathologies. Patents for the treatment of chronic ailments ensure future revenue from intellectual property rights. Stable management focuses on drug trials, where the latest mark stands at 30.70. The quarterly EPS growth trend clearly demonstrates the real efficiency of capital value generation and hidden business risks.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan biovieinc.com (BIVI): kanggo periode 04.07.2022 - 14.11.2026

Ringkesan rincian data analitis BioVie (BIVI)

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham BioVie Inc|BIVI - Bagan rega target

- indikator valuasi pasar bisnis:

Kapitalisasi pasar BioVie Pharma|BIVI - Total Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham BioVie|BIVI - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku biovieinc.com|BIVI - Aset Agregat Perusahaan

- data liabilitas lan likuiditas perusahaan:

- rincian bathi lan kelipatan pasar:

BIVI - Penghasilan resik perusahaan|Bathi mangsa ngarep BioVie Inc.|BIVI - Nilai perusahaan marang bathi resik|Pangali Forward P/E BioVie Inc.|BIVI - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioVie Inc|BIVI - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) BioVie|BIVI - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan biovieinc.com|BIVI - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep BioVie Inc.

- indikator pendapatan dodolan lan penghasilan bisnis:

BIVI - Pendapatan perusahaan|Prakiraan volume dodolan BioVie Inc.|BIVI - Koefisien rega marang pendapatan|Multiplikator forward rega marang pendapatan BioVie

Analisis komprehensif perusahaan:BioVie Inc., BIVI

The development of BioVie Inc. (BIVI) depends directly on the outcomes of clinical trials for drugs targeting cirrhosis and Alzheimer's disease. An analysis of quarter-over-quarter EPS dynamics reflects changes in net income per share, accounting for tax adjustments and subsidies, allowing for the timely detection of a systemic decline in business efficiency and the avoidance of capital freezes amidst high R&D risk volatility.

Pesaing langsung

ARWR (Arrowhead Pharmaceuticals Inc) - Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan|MIRM (Mirum Pharma) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|DVAX (Dynavax Corp) - Wutah bathi EPS kuartalan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan arbutusbio.com ABUS|Wutah bathi EPS kuartalan IVA|GYRE (Gyre Therapeutics) - Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ASMB (Assembly Bio)|Wutah bathi resik saben saham sajroning taun lumaku Galectin|Genfit Corp - Wutah bathi EPS kuartalan|DRRX - Wutah bathi EPS kuartalan|ALGS: Wutah bathi EPS kuartalan|GLMD (Galmed Pharma) - Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan ENDRA|hepionpharma.com (HEPA) - Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan